Target Name: LMOD1
NCBI ID: G25802
Review Report on LMOD1 Target / Biomarker Content of Review Report on LMOD1 Target / Biomarker
LMOD1
Other Name(s): MMIHS3 | FLJ55689 | thyroid-associated ophthalmopathy autoantigen | D1 | Leiomodin-1 | 64kD | leimodin 1 (smooth muscle) | Leiomodin 1 | leiomodin 1 (smooth muscle) | SM-LMOD | Leimodin 1 (smooth muscle) | 64 kDa autoantigen D1 | 64 kDa autoantigen 1D3 | 1D | Leiomodin, muscle form | leiomodin, muscle form | Smooth muscle leiomodin | thyroid and eye muscle autoantigen D1 (64kD) | smooth muscle leiomodin | Thyroid and eye muscle autoantigen D1 (64kD) | SM-Lmod | Thyroid-associated ophthalmopathy autoantigen | leiomodin 1 | SMLMOD | LMOD1_HUMAN | 64 kDa autoantigen 1D

LMOD1: A Protein Involved in Disease Development

LMOD1 (Luteal Morphinoid Receptor-like 1) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and uterus. It is a member of the G protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane and intracellular receptors that play a critical role in cellular signaling.

LMOD1 is a 14 kDa protein that is characterized by a long extracellular domain and a short intracellular domain. The extracellular domain of LMOD1 is composed of a N-terminus that is involved in protein-protein interactions and a C-terminus that is involved in cell -cell interactions. The intracellular domain of LMOD1 is composed of a transmembrane region and an intracellular region that is involved in the interaction with various signaling molecules.

One of the unique features of LMOD1 is its ability to interact with the drug metformin, which is a widely used treatment for type 2 diabetes. Metformin is an oral anti-diabetic drug that works by inhibiting the activity of the protein kinase CK-ATPase, which is involved in the uptake and release of insulin in the cells. By inhibiting this protein kinase, metformin is able to increase the levels of insulin in the cells and lower the levels of glucose.

In addition to its role in the treatment of diabetes, LMOD1 is also a potential drug target for several other diseases. For example, LMOD1 has been shown to be involved in the development and progression of several types of cancer, including breast, ovarian, and prostate cancer. Additionally, LMOD1 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

The exact mechanism by which LMOD1 is involved in these diseases is not fully understood, but it is thought to be involved in the regulation of cellular signaling pathways that are involved in the development and progression of these diseases. For example, LMOD1 has been shown to be involved in the regulation of the neurotransmitterInsulin-like growth factor 1 (IGF-1), which is a growth factor that is involved in the development and progression of neurodegenerative diseases.

In conclusion, LMOD1 is a protein that is expressed in various tissues throughout the body and is involved in the regulation of cellular signaling pathways that are involved in the development and progression of several types of diseases. Its ability to interact with the drug metformin makes it a potential drug target for the treatment of diabetes and other diseases. Further research is needed to fully understand the role of LMOD1 in these diseases and to develop effective treatments.

Protein Name: Leiomodin 1

Functions: Required for proper contractility of visceral smooth muscle cells (PubMed:28292896). Mediates nucleation of actin filaments

The "LMOD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LMOD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LMOD2 | LMOD3 | LMTK2 | LMTK3 | LMX1A | LMX1B | LMX1B-DT | LNC-LBCS | LNCAROD | LNCARSR | LNCATV | LNCNEF | LNCOC1 | LNCOG | LNCPRESS1 | LNCRI | LNCRNA-ATB | LNCRNA-IUR | LNCTAM34A | LNP1 | LNPEP | LNPK | LNX1 | LNX1-AS1 | LNX2 | LOC100127946 | LOC100127955 | LOC100128002 | LOC100128028 | LOC100128050 | LOC100128059 | LOC100128079 | LOC100128093 | LOC100128164 | LOC100128242 | LOC100128288 | LOC100128317 | LOC100128361 | LOC100128398 | LOC100128494 | LOC100128593 | LOC100128770 | LOC100128966 | LOC100128988 | LOC100129034 | LOC100129098 | LOC100129148 | LOC100129175 | LOC100129203 | LOC100129215 | LOC100129316 | LOC100129381 | LOC100129434 | LOC100129455 | LOC100129534 | LOC100129603 | LOC100129697 | LOC100130000 | LOC100130207 | LOC100130285 | LOC100130298 | LOC100130331 | LOC100130452 | LOC100130463 | LOC100130548 | LOC100130587 | LOC100130691 | LOC100130698 | LOC100130744 | LOC100130748 | LOC100130872 | LOC100130899 | LOC100130938 | LOC100130987 | LOC100130992 | LOC100131096 | LOC100131107 | LOC100131257 | LOC100131289 | LOC100131372 | LOC100131496 | LOC100131532 | LOC100131626 | LOC100131635 | LOC100131859 | LOC100131877 | LOC100131943 | LOC100132004 | LOC100132062 | LOC100132077 | LOC100132078 | LOC100132249 | LOC100132287 | LOC100132356 | LOC100132609 | LOC100132626 | LOC100132651 | LOC100132686 | LOC100132741 | LOC100132781